Lasa Supergenerics files another suit for permanent injunction against one of its competitors

10 Mar 2022 Evaluate

Lasa Supergenerics has filed a suit for Permanent injunction restraining infringement of its Patent, Tortious interference, Confidential Breach and Misuse of information, unfair trading etc. rendition of accounts and damages in respect of Indian Patent no. 326628 in respect of an invention titled “An Improved Process For The Preparation Of Methyl 5 (Propylthio)-1h-Benzo [D] Imidazol-2-Ylcarbamate”,which protects the process for manufacture of a product named Albendazole, filing aimed to prevent the unauthorised use and disclosure of the confidential information owned by Lasa, to prevent the acts of interference in the business activities, to prevent interference in contractual obligations, to prevent the inducement and incitement to the contractual employees, unfair trading before the Commercial Division of the Hon’ble Bombay High Court against Lohita Lifescience and others.

This could be yet another milestone for Lasa, as it may restrain its competitors from manufacturing and dealing in one of the key product and enables the company to continue its leadership for its key products worldwide.

Lasa Supergenerics is pioneer and amongst the leading players in the manufacturing of APIs in India through its catalyst chemistry expertise and fully backward integrated unit.

Lasa Supergenerics Share Price

28.19 0.88 (3.22%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.